A standoff over Elevidys could have major consequences for Duchenne patients, gene therapy companies and the perception of the FDA.One month ago, a 51-year-old man treated in a clinical trial with an experimental gene therapy became dangerously sick. The developer of that treatment, Sarepta Therapeutics, informed the Food and Drug Administration his case could be […]
